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Clinical pilot study with cyclosporin G (CyG) in kidney transplant
recipients. B. Huser, J, Landmann, M.J. Mihatsch, L. Bianchi, G.
Thiel, Division of Internal Medicine, Surgery and Pathology, Cantonal
Hospital, Basle, Switzerland. Animal experimental studies comparing
CyG and cyclosporin A (CyA, Sandimmun) showed that they are
equipotent as regards their immunosuppressive action, but CyG was
told to be less nephrotoxic. We used CyG as an immunosuppressant in
12 first cadaveric kidney transplant recipients during the first 3 months
post-transplant (initial dose 12 mg/kg, prednisone 0.5 mg/kg). After this
period the patients were switched to CyA. The historical control group
consisted in 38 first cadaveric kidney transplant recipients treated with
CyA at the same dosage. In the first 6 months of the observation period
I out of 12 patients died (corynebacterial sepsis) in the CyG group and
2 out of 38 (pancreatitis, herpesvirus I sepsis) in the CyA group. Two
out of 12 patients in the CyG group required nephrectomy (renal arterial
thrombosis, vascular rejection) and 3 out of 38 patients in the CyA
group required nephrectomy (3 x vascular rejection). One out of 12
patients in the CyG group required a change to conventional treatment
(CyG nephrotoxicity) and 3 out of 38 patients in the CyA group required
a change to conventional treatment (CyA nephrotoxicity). There were
no problems with the kidney in 9 out of 12 patients in the CyG group and
30 out of 38 patients in the CyA group. Whole blood trough levels of
CyG were significantly higher after 4 weeks of treatment, the dosage
however not (unpaired t-test P < 0.01). There was a trend to higher
serum creatinine levels in the CyG group. In the CyG group bilirubin
and ALAT levels rose significantly (jaundice in 8 out of 12 patients).
Histological examination of the liver revealed evidence of tissue
damage in 4 examined patients. Conclusion: The number of irrever-
sible rejection reactions was comparable in the two groups as did
survival rate of patients. We could not confirm that cyclosporin G is
less nephrotoxic than cyclosporin A, but the number of patients is
small. Cyclosporin G has pronounced hepatotoxicity at the dosage
used.
Raised bone alkaline phosphatase (AP) levels in patients (PTS) on
cyclosporine A (CyA): Bone disease or repair? V. Briner, F.P. Brunner,
J. Landmann, E. Ritz, M.A. Dambacher, G. Thiel, Departments of
Medicine and Surgery, Univ. Basle, Switzerland, University Hospital
Heidelberg, Federal Republic of Germany, Orthopaedy, University
Hospital Zurich, Switzerland. Increasing AP levels were recorded in 50
(36%) of 139 PTS on CyA following renal transplantation (PT). Clinical
or biochemical evidence of liver disease or toxicity was lacking.
Isoenzyme analysis confirmed the bone as source of elevated AP levels.
AP started to rise 3 3 months PT and reached maximum levels of 242
103 U/liter (normal up to 107 U/liter). In 32 of the 50 PTS AP levels
returned to normal after another 14 6 months. They remained
elevated in 18 PTS during a follow up of 6 to 62 months. Symptoms of
bone disease were lacking. Radiological mean score of hyperparathy-
roid bone disease (hand X-rays) was 2.7 at transplantation in PTS with
a subsequent rise and 1.0 in those without a rise in AP PT (P < 0.01).
Mean radiological score improved after a follow up of one year or
more.
Cyclosporine A
AP increased AP normal Azathioprine P
iPTH-C ng/m/ 167 (median) 120 (median) 98 (median) NS
IPTH-N ng/ml 0.54 (median) 0.38 (median) 0.22 (median) NS
1.25 (OH)2Vit.D3 238 178 196 120 184 127 NS
pmol/liter
Serum calcium 2.55 0.1 2.48 0.1 2.25 0.2 NS
mmol/liter
% TRP 62 12 65 12 63 13 NS
Conclusion: (1.) Bone AP levels increased in 1/3 of PTS treated with
CyA PT. (2.) These patients have more radiological evidence of
hyperparathyroid bone disease at transplantation which improved on
follow up. (3.) The increase in AP levels thus appears to indicate rather
repair than bone disease.
Differences in the effects of azathioprine (AZA) and sandimmun(R)
(CYA) on erythropoiesis after kidney transplantation. M. Tschudi, J.
Landmann, S. Brunner, G. Thiel. Nephrologie, Departement Innere
Medizin, Kantonsspital und Universitätsklinik Basel, and Institut Viol-
her, Basel, Switzerland. We compared the effects of immunosuppres-
sive treatment with Aza (N = 60) and CyA (N = 58) on erythropoiesis
in the first 24 months following kidney transplantation. Results. In the
first 3 months post-transplant the Hb values in both groups rose in an
almost identical manner. From months 4 to 12 post-transplant the Hb
values in the CyA group were significantly lower, with differences of the
order of 1.1 to 1.7 g%. This difference is attributable solely to the
somewhat poorer renal function in the CyA group (nephrotoxicity), as
is apparent from regression analyses between Hb and serum creatinine.
At all times (1/2 month to 2 years post-transplant) the mean MCV values
were significantly greater in the Aza group than in the CyA group.
Polycythaemia (Hb = 18g%)was observed in 11 out of 60(18%) patients
in the Aza group and only in 3 out of 58(5%) (P <0.001) patients in the
CyA group, although the proportion of patients suffering from cystic
disease of the kidney was the same in both groups. The serum
erythropoietin levels, measured by means of an erythropoietin enzyme
immunoassay, were higher in all kidney transplant recipients as com-
pared with a control group without kidney disease (N = 103) (110 54
as compared with 84 16 miU/ml SD) (P < 0.001) although there were
no differences between the two groups of kidney transplant recipients.
Summary. Kidney transplant recipients treated with CyA differed from
those treated with Aza in having slightly lower haemoglobin levels,
reflecting poorer renal function, as well as in the fact that they did not
suffer from macrocytosis and showed evidence of polycythemia on
fewer occasions. These differences cannot be explained on the basis of
the underlying renal disease (cystic kidneys or secondary cysts in
shrunken kidneys) or on the basis of differences in erythropoietin
levels.
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Short—term effects of mineralocorticoids on urinary acid excretion in
the adrenalectomized rat. H. Gui/lain, M. Nenniger, J. Diezi, Inst it ut de
Phar,nacologie, Bugnon 21, 1005 Lausanne, Switzerland. The short—
term effects (within 5 hr) of aldosterone (aldo) on urinary acid excretion
were studied by clearance techniques in 24 hour adrenalectomized
(ADX), anesthetized male rats. Ten, 30 minute clearance periods were
carried out and H concentration (H'), titratable acidity (TA), ammo-
nium excretion (NH4) and total acid excretion (TAB) were measured in
urine. All animals were substituted with a glucocorticoid
(dexamethasone 3.5 sg/kg i.p. + 1.2 pg/kg. hr i.v.) to maintain
glomerular filtration rate (GFR). The mineralocorticoid effects were
studied under various conditions of acute acid load: 4 groups (AGI to
AG4) received an infusion solution containing Na2SO4 (80 to 105 mM)
and HC1 (acid delivery: 0, 0.22, 0.54 and 1.08 mmoles Hi/kg hr,
respectively), and aldo was injected (2 sg/kg) and infused (2 jsglkg . hr)
after the first 30-minute control period. In 4 control groups (CG1 to
CG4) rats were treated similarly, except for aldo administration. Within
30 to 60 minutes H increased significantly in AGI to AG4. Max H
values were 3- to 5-fold higher than in control period. The time course
of this effect was similar to that observed previously with urinary Na
and K excretion. H remained constant or decreased in control groups.
Within 3 hours aldo enhanced TA and TAE in AG!, AG2 and AG3, but
not in AG4. Aldo also increased NH4 in AG!, AG2 and AG3, but to a
lesser extent. GFR was similar in controls and aldo treated animals. In
all groups TAB was directly related to the degree of the acid load. The
effect of aldo was rnineralocorticoid—specific since rats given equimolar
doses of dexamethasone did not differ from controls. Thus, in ADX rats
aldo provokes a rapid rise in urine H'' concentration and increases
within a few hours urinary total acid excretion, mostly by enhancing
TA.
Body sodium, atrial natriuretic factor and cardiovascular reactivity:
Adaptation to dietary sodium in relation to familial predisposition to
essential hypertension. C. Beretta—Piccoli, C. Pusterla, P. Stddler, P.
Wejdmann, S. Shaw, Ospedale Italiano, Lugano, and Medizinische
(Jniversitiitspoliklinik Berne, Switzerland. In normotensive subjects
with familial predisposition to essential hypertension the blood pressure
could be sodium—sensitive. Possible mechanisms of sodium—sensitivity
were studied. Body sodium, the cardiovascular pressor reactivity to
norepinephrine (NE) or angiotensin II (All) plasma levels of NE,
epinephrine, renin, All, aldosterone and atrial natriuretic factor (ANF)
were measured on low (15 mmol/day) or high (270 mmol/day) sodium
diet in 10 normotensive young men without and 13 with family history
of essential hypertension. On the low sodium diet, the 2 groups did not
differ in mean arterial pressure, heart rate, body weight and the
considered pressor factors. The change from the low to the high sodium
diet was associated with a significant (P < 0.05) increase in systolic
blood pressure in predisposed subjects without variations in the non-
predisposed subjects. Exchangeable body sodium, body weight, ANF
(from 29 15 (SD) to 45 23 pg/mI and from 28 9 to 35 11 pg/ml)
increased significantly (P < 0.05) and to a comparable extent in the two
groups. Plasma NE, epinephrine, renin All and aldosterone levels were
also equally suppressed. The pressor reactivity to infused NE or All, as
assessed by the relationship between the NE or All—induced increased
in blood pressure and the plasma concentration of NE or All were
significantly shifted to the left (P < 0.05) by the high as compared to the
low sodium diet; the degree of shifting did not differ between the two
groups. The findings of this investigation appear to confirm that a high
dietary sodium intake could have a selective pressor effects in normo-
tensive subjects with familial predisposition to hypertension. This effect
is not explained by an abnormal adaptation of body sodium, ANF and
cardiovascular pressor reactivity to NE or All.
Technical developments of continuous ambulatory peritoneal dialysis—
summary of own experiences. U. Binswanger, G. Bichsel, Nephro-
/ogische Station, Dept. für Innere Medizin, Universitãt Zurich und
Grosse Apotheke Interlaken, Switzerland. A disposable double—bag
system connecting a large dialysate delivery bag and an empty large
effluent bag by a Y-piece allows individual dialysate volumes to be
instilled and drainage at low pressure inside the effluent bag in case of
large ultrafiltration volumes. Removal of the set during the interval of 2
filling phases is well accepted by patients; it includes no more doubling
of disconnections as comapred to conventional one bag systems since
the introduction of an "occluding cutter". The initial movement of
dialysate from the abdomen into the effluent bag as simulated in vitro
results in a reduction of bacteria to 1% of a contaminating inoculum;
internal sterilization was not found to be useful in a study in patients.
Switching from a one bag system to the one described before resulted in
50% reduction of the peritonitis rate. Separate sterile inclusion of agents
is possible by means of a breakable chamber built into the dialysate bag.
Further progress in the treatment by continuous ambulatory peritoneal
dialysis is expected to emerge from knowledge of physiologic and
pathophysiologic events inside the peritoneum rather than from addi-
tional technical developments.
Phosphate binding in vitro of some products used in patients. U.
Binswanger, with the technical assistance of E. Huber, Nephrologische
Station, Universitatsspital, Zurich, Switzerland. The phosphate binding
capacity of one dose generally prescribed was estimated by simulating
exposure to an acid (stomach) and alkaline environment (small intes-
tine) and expressing it as percent absorption from 20 ml of a 0.3%
phosphorus solution as recommended elsewhere. Results were as
follows:
Preparation
Dose
g
Al (011)3 content
mg % binding
Al (OH)3 2 cps 800 73.1
Al (OH)3
+ Mg (OH)2 2 tbl 750 60.9
Al (OH)3
+ Mg (OH)2 2 tbl 450 62.1
+ Ca CO3
Al (OH)3
gel 20 ml
lOmI
2 ml
1,500
750
150
49.8
34.0
9.7
It is concluded that similar phosphate binding can be obtained by
mixing available compounds and thereby reducing the amount of Al
(OH)3. The dry weight of substance given to the patient increases by a
factor of three. As shown earlier, gel preparations are less active; its
binding capacity is augmented less as might be expected from the Al
(OH)3 content of increasing doses.
Behaviour of 2.microglobulin in patients undergoing maintenance
hemodialysis, hemodiafiltration and continuous peritoneal dialysis. A.
Blumberg, W. Burgi, Kantonsspital Aarau, Switzerland. Recently a
new form of amyloid has been described in patients (pts) maintained by
long—term hemodialysis (HD). Its major component was found to
consist of 132-microglobulin (/32-m). For this reason we studied the
behaviour of j32-m in pts undergoing HD and continuous peritoneal
dialysis (CAPD). In 52 pts on HD, serum f32-m was markedly elevated
to 37.9 1,4 mg/liter (normal 1.2 0.6). It was correlated with duration
of HD (r = 0.43, P < 0.01) and inversely with residual renal function (r
= 0.87, P < 0.001). In 20 CAPD pts a similar elevation of /32-m to 31.6
2.3 mg/liter was found. f32-m was dialyzable by the peritoneum but
daily elimination amounted to only 34 mg (normal 150 mg). Contrary to
HD with a cuprophane membrane that caused a rise, hemodiafiltration
with a polysulfone membrane was accompanied by a decrease in serum
pz-m levels. In 5 pts treated over 2-1/2 months concentrations fell from
39.5 0.7 to 29.7 1.0 mg/liter predialysis. However, f32-m elimination
was only around 100 mg/day in the presence of markedly—elevated
serum concentrations. In order to obtain relatively low /32-m levels,
very large quantities of hemofiltrate would be necessary.
Acute vascular lesions in renal allografts. H.R. Burger, G. Keusch
Largiadêr F., Binswanger U. Institut für Pathologie, Nephro/ogische
Abteilung und Viszera/chirurgische Klinik Universitatsspisal Zurich,
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Switzerland. In 16 out of 254 renal biopsies (Bx) from 152 renaltranspl-
ant recipients, we found thrombotic microangiopathic vascular lesions.
The clinical indications for Bx were as follows (number of cases):
rejection episode resistant to prednisone pulse therapy (7); hemolytic
uremic syndrome (HUS) (7); prolonged post-transplant renal failure (2).
The vascular lesions were characterized by (number of cases): arteri-
olopathy with fibrinoid insudation and/or edema in the vascular wall
(14); endothelial damage in the glomerular capillary loops with enlarge-
ment of the subendothelial space by insudation of plasma (8); endothe-
hal damage in the arteriolar vessels (4); microthrombi in the glomeruli
(7) and in the arterioles (I). The clinical analysis in association with the
morphological findings led to the following causes of thrombotic vas-
cular lesions (number of cases). In patients treated with Cs (N = 13): Cs
toxicity (2); Cs toxicity in a transplant with pre-existing hypertensive
vasculopathy (2); vascular and cellular rejection (3); intravascular
coagulation in a transplanted shock—kidney (I); no classification possi-
ble (5). In patients treated with conventional immunosuppression (N =
3): hyperacute vascular rejection (2); recurrence of HUS (1). Conclu-
sions. Thrombotic microangiopathic vascular lesions may be due to
various causes and an exact classification is not always possible.
Evidence for a beneficial effect of plasma exchange in lupus nephritis.
R. Christen, G. Keusch, J. Gmiir, H.R. Burger, U. Binswanger,
Medical Clinic, Department of Pathology, University Hospital of
Zurich, Switzerland. We examined the impact of plasma exchange (PE)
on the long term course of active lupus nephritis in 7 female patients
(age 21—48 years, mean 32). Before starting PB all patients had renal
failure (serum creatinine level ranged from 154—673 imol/liter; mean
417 248), proteinuria (3.0—12.3 g/day, mean 6.2 3.4) and hematuria.
Renal biopsies were performed before PB in 5 cases and showed a
diffuse membranoproliferative glomerulonephritis in 4 cases and a focal
membranoproliferative glomerulonephritis in one case, respectively.
PE was carried out with the Haemonetic Model 50 blood cell separator.
The volume of plasma removed (2.3—4.1 per run) was replaced by
human plasma—protein fraction (PPL, SRK-Human). Seven to 135 runs
(mean 36) were performed over a period of 13 to 1619 days. At the time
of PB all patients received prednisone in combination with azathioprine
or cyclophosphamide. The course of renal failure was analyzed by
plotting the reciprocal values of the serum creatinine versus time. The
mean period of analysis before and after initiation of PB was 24 and 37
months, respectively. Before PE renal function was deteriorating
rapidly in all 7 patients. After PE renal function improved in 3 patients,
stabilized in I patient and deteriorated at a slower rate compared to the
pretreatment period in 2 patients. No beneficial effect of PE on renal
function was observed in I patient. We conclude that PB combined with
immunosuppressive drugs may have a favorable impact on the long time
course of lupus nephritis.
Effect on the lipid metabolism of conventional heparin (H) treatment
and low molecular weight heparin (LMWH) in hemodialysis patients
(CHP). TH. Collaud, G. Guelpa, W. Riesen, D. Robert, Hôpital Ia
Providence Neuchdtel. Cancer Research, Berne, Switzerland. Heparin
is an activator of lipoprotein hipase (LPL). Chronic use of heparin could
be responsible for the diminution of lipolytic activity observed in CHP.
We have undertaken a study to compare the influence of chronic
administration of H or LMWH on the lipid metabolism of CHP.
Patientsand methods. Ten CHP (6 women, 4 men, mean age 58 years)
were studied in different conditions: (1) Heparin (HeparineR Novo) with
a mean dosage of 30 U/kg body wt (day 0). (2) LMWH (FragmineR
Kaby)at high dose of 60 U/kg body wt(day 1,5,21). (3) LMWH at low
dose 35 U/kg body wt at day 50. After overnight fasting, blood samples
were taken for determination of the serum concentration of total
cholesterol (CH), triglycerides (TG), VLDL-CH and TG, LDL-CH and
TG, HDL-CH and TG, ApoAl ApoB and basal activity of LPL and
HTGL. Ten minutes after injection of H or LMWH a second blood
sample was taken for determination of LPL and HTGL activity.
Results. With H, LPL activity was 9.58 1.12 /s M FFA/nl and
significantly lower with LMWH. At day 1: 7.65 1.87, NS; at day 5:
6.33 2.02 P< 0.002; at day 21: 4.61 1.025 P<0.001; at day 50: 5.01
0.91 P < 0.001. No significant differences were found for HTGL
activity and for TG, CH, VLDL-CH, VLDL-TG, LDL-CH, LDL-TG
and HDL-CH. However HDL-TG was significantly higher after day 5;
day 0: 0.25 + 0.05 mmol/liter; day I: 0.27 + 0.12 NS; day 5: 0.36 0.14,
P < 0.02; day 21: 0.43 0.23, P < 0.02; day 50: 0.39 0.14, P < 0.05.
Conclusion. LMWH does not release LPL from the vascular wall to the
same extent that H. The increase of the concentration of HDL-TG
needs further investigation in order to determine whether there is a
protective effect atheromatous complications.
Influence of low molecular weight heparine (LMWH) on blood picture
and hipoproteids. H.J. Deuber, W. Schulz III, Med. Klinik, Klinikum
Bamberg, Akad. Lehrkrankenhaus der Univ. Erlangen, Nfirnberg,
Germany. The new LMWH shows several advantages in comparison
with the conventionally used heparine (CH). There are reports about
decreased fatty acids and a minor allergization potency. The aim of this
study was to investigate the alterations in blood picture and lipopro-
teins. Methods. Eleven patients, aged 42—66 years, being hemodialyzed
since 1/4 to 5 years, were treated with LMWH for 3 months. The
laboratory findings during LMWH-dialysis were compared with those
during CH-dialysis. Results. The data are given as CH vs. LMWH.
Leucocytes, 7718 2562 vs. 8150 2O88/pi (NS); monocytes, 2.4 2.7
vs. 9.8 9.2% (P< 0.05); eosinophiles, 5.0 5.6 vs. 2.3 2.7% (P <
0.05); HDL, 145.2 55.9 vs. 182.0 92 mg/dl (NS); LDL, 354.4 44.4
vs. 320.7 82 mg/dl (NS). Conclusion. The reduction of eosinophiles
indicates the minor allergization potency of LMWH compared with
CH. The rise of HDL indicates a possible reduction of the arterioscle-
rotic risk by LMWH.
Improved stability of circulation during computer modelling dialysis
(CMD). H.J. Deuber, W. Schulz, W. RebstOck III, Med. Klinik,
Klinikum Bamberg, Akad. Lehrkrankenhaus der Univ. Erlangen,
Nih-n berg, Germany. Many patients show tachyarrhythmias or
hypotensions during normal hemodialysis (ND). The CMD allows a
freely programmable control of ultrafiltration rate (U FR) and of sodium
concentration (SC) at any time throughout dialysis according to the
clinical demands and therefore makes it possible to cope with these
cardiovascular problems. Methods. Four patients (51, 56,61,66 years)
were treated with different UFR and SC that were developed for
individual purposes. The heart rate (HR) and the blood pressure (BP)
during CMD was compared with the intraindividual values during ND.
Results. Starting with compareable HR and BP there was a marked (P
< 0.05) reduction of heart rate from 121.6 9.8/mm (ND) to 107
13.8/mm (CMD) and a marked (P < 0.05) increase of BP from 139.3
15.3 mm Hg (ND) to 169.7 3.1 mm Hg (CMD). During CMD no
cramps occured that were quite common during ND. Conclusion. For
cardiovascular instable patients CMD provides a more careful form of
dialysis by adaptation of UFR and SC to the patient's individual
tolerance.
Liver function in stable renal transplant patients. F.J. Frey, H.J.
Schaad, E. Renner, R. Preisig. Medical Policlinic and Department of
Clinical Pharmacology, University of Berne, Berne, Switzerland. The
incidence of liver failure increases more than 3 times after kidney
transplantation (KT). The purpose of the present investigation was (I.)
to define the course of the impairment of liver function between 1 month
and 1 year after KT and (2.) to assess the influence of the altered liver
function on the systemic availability (F) of prednisolone (FP) and
cyclosporine A (FCyA). Therefore the following determinations were
performed in stable KT patients on CyA and P maintenance therapy I
month and 1 year after KT: FP, FCyA; clearance of P (CP), CyA
(CCyA) and caffeine (CC); elimination capacity of galactose (GEC).
The group was made up of 12 males and 8 females; three were HB AG
positive and in 3 ALAT was slightly (<3 x upper limit) increased.
Results I month 1 year N P <
CP mI/mm/kg 2.1 0.3 1.7 0.3 18 0.01
FP% 81 12 75 18 18 NS
CCyA mI/mm/kg 6.5 2.2 5.0 1.3 17 0.05
FCyA % 37 13 20 5 17 0.001
CC mI/mm/kg 1.9 0.9 1.3 0.6 13 0.03
GEC g/kg body wt 6.1 1.0 6.0 0.9 18 NS
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The results show that during the course of sucessful KT maintenance
hepatic impairment was accentuated more by reduced microsomal (CP,
CCyA, CC) than by reduced cytosolic function (GEC). The plasma
concentrations of CyA or prednisolone after oral dosing were the same
I month and 1 year after KT because the decrease in F was set off by
a decrease in C of CyA and P 1 year after KT.
Distinct distribution of periarticular erosions of the hand skeleton in
dialysis patients. Bernhard Gerber, Fritz F. Horber, Guido Robotti,
Jurg R. Scheidegger, Felix J. Frey, Medizinische Poliklinik and De-
partinent of Diagnostic Radiology, University of Berne, Berne, Swit-
zerland. The frequency of radiological changes of the hand skeleton in
142 patients on hemodialysis, 19 on CAPD and 15 with advanced renal
insufficiency not requiring dialysis was analyzed. Forty—seven percent
of all patients had subperiostal cortical bone resorptions, 31%
periarthritis calcarea, 22% periarticular erosions, 3% chondrocalcinosis
and 1% aseptic necrosis. Sixty—six percent of the periarticular erosions
were observed in the distal and proximal interphalangeal joints of
fingers II, III, IV and V, whereas only 33% were found in the remaining
joints (120 vs. 62, P < 0.001). The distal interphalangeal joints showed
about 70% more often periarticular erosions than the proximal inter-
phalangeal joints (77 vs. 43, P < 0.001). Since patients with chronic
renal failure exhibit a decreasing incidence of periarticular erosions
from the distal interphalangeal joints to the intercarpal joints, while
patients with rheumatoid arthritis have their erosions preferentially
localized in the proximal interphalangeal, metacarpophalangeal and
wrist joints, it can be concluded that renal osteodystrophy causes a
distinct distribution of periarticular erosions of the hand skeleton.
Plasma levels and dialysance of atrial natriuretic peptide in terminal
renal failure. M.P. Gn/idinger, H. Saxenhofer, P. Weidmann, S. Shaw,
D.E. Uehlinger, C. Descoeudres. Medizinische Poliklinik, University of
Bern, Switzerland. Circulating atrial natriuretic peptide (ANP) in-
creases in normal man with aging and in response to raised blood
volume, blood pressure (BP) or the change from standing to recum-
bency. Since previous reports of high plasma immunoreactive ANP
levels (irANP) in hemodialysis patients (HDP) did not consider possible
influences of age and posture, we evaluated these aspects as well as the
dialysance of circulating irANP in HDP without evidence of heart
failure. In the supine position, plasma irANP averaged 144 53 (±
SEM) pg/mI in 12 normal subjects (NoS) (mean age 63 2 yr). In 42 HDP
(mean age 65 1 yr), plasma irANP was elevated (447 50 pg/mI, P <
0.01) before dialysis and decreased (P < 0.001) to 164 24 pglml after
4 hr of dialysis. The latter reduced mean body weight by —2.3 0.2 kg
(P < 0.001) and BP from 139 4/77 2mm Hg to 126 4/73 2mm
Hg(P <0.01); compared with BP in NoS (126 5/79 2mm Hg), HDP
had a higher systolic BP before (P < 0.01); but not after HD.
Hemodialysis—induced changes in plasma irANP correlated inversely
with those in hematocrit (r =
—0.41, P < 0.01); while absolute irANP
values correlated significantly with systolic BP or age following dialysis(r 0.35 and 0.31, respectively; P < 0.05) but not before dialysis.
Compared with the supine position, plasma irANP after 1 hour of
upright posture decreased from 167 31 to 101 21 pg/mI (—40%, P <
0.01) in 12 NoS and from 1008 178 to 583 94 pg/mI (—42%, P <
0.01) in 8 HDP. Passage through the dialyzer (Prima M or HDS-10, N =
6) reduced plasma irANP from 530 146 to 397 119 pg/mI (—25%, P
<0.01) at the beginning and from 429 115 to 373 114 pg/mI (—13%,
P < 0.01) at the end of dialysis; with passage through a hemofilter (N
4), plasma irANP decreased from 625 128 to 324 63 pg/mI (—48%,
P < 0.05) and from 321 94 to 242 76 pg/mI (—25%, P < 0.05),
respectively. IrANP clearance from plasma averaged 24 5 mI/mm
across the dialyzer and 46 3 mI/mm across the hemofilter. Only Ii to
22% (dialyzer) or 15 to 67% (hemofilter) of irANP removed from plasma
were detected in hemodialysis fluid. Conclusions. In terminal renal
failure, circulating irANP is usually elevated before dialysis, raises with
the change from standing to recumbency and decreases towards normal
values after removal of excess fluid by dialysis. The elimination of
circulating irANP across dialyzers or ultrafilters can contribute only
little to the overall ANP regulation. In addition to the cardiac state, age
and posture should be considered when interpreting plasma irANP
levels as a possible index of sodium and fluid overload.
Short—term effects of mineralocorticoids in urinary acid excretion in the
adrenalectomized rat. H. Gui/lain, M. Nenniger, J. Diezi, Institut de
Pharmacologic, Bugnon 21, 1005 Lausanne, Switzerland, The short-
—term effects (within 5 hr) of aldosterone (aldo) or urinary acid
excretion were studied by clearance techniques in 24 hr adrenalecto-
mized (ADX), anesthetized male rates. Ten, 30 minute clearance
periods were carried out and H concentration (H), titrable acidity
(TA), ammonium excretion (NH4) and total acid excretion (TAE) were
measured in urine. All animals were substituted with a glucocorticoid
(dexamethasone 1.2 pg/kg- hr) to maintain glomerular filtration rate
(GFR). The mineralocorticoid effects were studied under various con-
ditions of acute acid load: 4 groups (AG I to AG4) received an infusion
solution containing Na2SO4 (80 to 105 mM) and HCI (acid delivery: 0,
0.22, 0.54 and 1.08 mmoles H/kg- hr, respectively), and aldo was
injected (2 gIkg) and infused (2 tg/kg . hr) after the first 30 minute
control period. In 4 control groups (CG 1 to CG4) rats were treated
similarly, except for aldo administration. Within 30 to 60 minutes H
increased significantly in AG1 to AG4. Max H values were 3- to 5-fold
higher than in control period. The time course of this effect was similar
to that observed previously with urinary Na and K excretion. H
remained constant or decreased in control groups. Within 3 hours aldo
enhanced TA and TAE in AGI, AG2 and AG3, but not in AG4. Aldo
also increased NH4 in AGI, AG2 and AG3, but to a lesser extent. GFR
was similar in controls and aldo-treated animals. In all groups TA and
NH4 were directly related to the degree of the acid load. The effect of
aldo was mineralocorticoid—specific since rats given equimolar doses of
dexamethasone did not differ from controls. Thus, in ADX rats also
provoked a rapid rise in urine H+ concentration and increases within a
few hours urinary acid excretion mostly by enhancing TA.
No evidence of hypersensitivity of 25-OH-D-la-hydroxylase to the
sodium content of the diet in Idiopathic renal stone disease. Ph. Jaeger,
T.L. Clemens, P. Burckhardt, Dept. of Internal Medicine, University
Hospital, Lausanne, Switzerland, and Columbia University, New York,
USA. High dietary Na-intake is a frequent finding in stone formers.
Recently a 10-day NaCl-enriched diet (250 mmol Na/day) given to
normal subjects has been shown to cause hypercalciuria, high PTH and
high l,25(OH)2D plasma levels. To examine whether idiopathic stone
formers (1SF) with chronically elevated Na-intake present a disturbance
of vitamin D metabolism, 30 1SF were studied on low-Ca diet (max. 0.4
g Ca/day for 5 days), on free—choice diet (—-0.8 g Ca/day) and on
Ca-enriched diet (+3 g Ca/day for 3 days). They were classified as 21
1SF with normal Na-intake (mean of 3 UNaV <200 mmol/24 hr, at most
I value comprised between 200 and 250) and 9 1SF with high Na-intake
(mean of 3 UNaV >275 mmol/24 hr, 3 values above 200). Plasma levels
of 25(OH)D were virtually identical and normal in both groups and were
not affected by the various diets. Plasma levels of 1 ,25(OH)2D which
also were normal in both groups were affected by the diets; however, in
contrast to what had been expected, the depression of 1,25(OH)2D
levels on high Ca diet and the rise of l,25(OH)2D on low Ca diet were
of similar magnitude in 1SF with high and in 1SF with normal Na-intake.
Furthermore, at any given intake of calcium, urinary calcium was
always significantly higher in the 1SF with high than in the 1SF with
normal Na-intake despite similar plasma levels of I ,25(OH)2D in both
groups. Conclusion. (1.) 1SF with high Na-intake do not show high
basal plasma levels of l,25(OH)2D, nor overstimulated la-hydroxylase
on low Ca diet, nor blunted suppression of this enzyme on high Ca diet.
(2) For a given plasma level of I ,25(OH)2D, 1SF with high Na-intake
have a higher urinary excretion rate of calcium than 1SF with normal
NA-intake; this suggests D-independent hyperabsorption of calcium in
case of chronically elevated consumption of sodium.
Modulation of leukopema, thrombocytopenia and protein adsorption of
3 hemodialyzer membranes: a comparison of dialyzer reprocessing tech-
niques. T. Kuwahara, M. Markert, and J.P. Wauters. Division de
Nephrologie et Laboratoire Central de Chimie Clinique, CHUV,
Lausanne, Switzerland. Dialyzer membrane re-use is claimed to im-
prove leukopenia. Therefore, cuprophane (CU), cellulose acetate (CA)
and polysulfone (PS) were compared successively in 4 patients after
reprocessing with 3% formalin (F), 1% hypochlorite-3% formalin (H-F)
or 4% peracetic acid (PA). With F, leukopenia improved from 26 to 76%
(P < 0.05 vs. 1st use) on CU, but worsened on CA from 59 to 41%.
Thrombocyte count was not modified on CU and worsened on CA from
97 to 88%. H-F did not modify the leukocyte and thrombocyte drop on
CU 27%, 93% respectively. It decreased the leukocyte drop on CA to
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44% and did not modify the thrombocyte count (97%). PA improved
leukopenia on CU to 92% and CA to 69%; thrombocyte count remained
unchanged on CU and on CA (97%). The leukocyte count (87%) and
thrombocyte count (96%) on PS were not influenced by these 3
techniques. Furthermore, fragments of CU, CA and PS were incubated
with plasma for 1 hour and stored with saline or reprocessed as
described above. Membrane fragments were then washed with saline
and the residual proteins removed with sodium dodecylsulfate and
quantified; electrophoresis was performed on polyacrylamide gel. With
saline storage, albumin was present on the 3 membranes but smaller
molecular weight proteins could be seen only on PS. Treatment with F
crosslinked the proteins which did not enter the gel. Storage with PA
altered the pattern of proteins on PS, where albumin disappeared and
only smaller molecular weight proteins were visualized. Conclusion. In
the present study, reprocessing with PA is the only method that
consistently improves leukopenia and thrombocytopenia. Furthermore,
adsorbed proteins are different for each membrane, and sterilization
procedures modify their pattern depending on the nature of the mem-
brane and the reprocessing technique.
An ATP-Regulated soluble 5'-nucleotidase of the rat kidney. M. Le
Hir, U.C. Dubach, Medizinische Universitaets—Poliklinik, Kantonspi-
tal, 4031 Base!, Switzerland. Adenosine is a regulator of renal hemo-
dynamics. The main source of adenosine in mammals is the hydrolysis
of 5'-AMP by 5'-nucleotidases. We purified a 5'-nucleotidase activity of
the high—speed supernatant of homogenates of the rat kidney. The
enzyme is devoid of activity towards 2'- and 3'-AMP, ADP and ATP.
With 200 sM of substrate the rate of hydrolysis of 5-IMP and of
5'-GMP are 55% and 53%, respectively, as compared to 5'-AMP. In the
range pH 6.4 to pH 7.4 a 0.4 units drop of the pH provokes a roughly
50% decrease of the rate of hydrolysis of 5'-AMP. This could explain
why the intracellular acidification during hypoxia protects 5'-AMP
against hydrolysis. The Km for 5'-AMP is about 65 LM in the presence
of physiological concentrations of ATP instead of 9.5 lM in the absence
of ATP. Decreasing the concentration of ATP in the physiological range
provokes a marked decrease of Vmax. This might be related to the
increased production of adenosine which is observed during accelerated
catabolism of ATP. Thus, the kinetic properties of the soluble 5'-
nucleotidase suggest that it might play a major role in the hydrolysis of
5-AMP to adenosine in viva.
Switching from cyclosporine (CyA) to azathioprine (Az) 6 months after
renal transplantation—experience of 26 consecutive cases. M. Levy, M.
Leski, A Spiliopoulos. Division de Nephrologie et Clinique de Chirurgie
Thoracique, Hdpital Can tonal Universitaire de Genève, Switzerland.
CyA has improved the results of kidney transplantation. Nevertheless
its renal and extrarenal toxicity has induced some authors to change
immunosuppressive regimen after three or more months. We have
transplanted 37 patients between October 1983 and May 1985. Four
transplants failed during the first 2 months: one patient died after one
month of a cerebrovascular accident with a functioning kidney; an
irreversible rejection happened in a patient affected by a systemic
lupus; two other kidneys failed because of early arterial thrombosis.
Seven other patients were removed from the switching program be-
cause of diabetes, hepatitis or leukopenia. Our protocol combines low
doses of prednisone (P) to CyA and P was given at the same doses
during 2 months after switching. A dose of 2 mg/kg/d of Az was given
from the day when CyA was stopped. The results were excellent for 18
patients (69%): 7 others had a steroid sensitive rejection occurring one
to seven weeks after the switch and the last showed a severe nephrotic
syndrome 2 months after the switch. In conclusion switching from CyA
to Az carries an important risk of rejection and high dose steroid
treatment. The loss of the transplant is very scarce but deserves
attention.
Transport of organic cations in pig renal brush border membrane
vesicles (BBMV). F. Martinez, C. Rafizadeh, D. Werner, C. Schäli,
Roch—Ramel F. Institut de Pharmacologic de I' Université, 1005
Lausanne, Switzerland. The transport of two organic cations, N1-
methylnicotinamide (NMN) and tetraethylammonium (TEA) were stud-
ied in renal BBMV of the pig kidney. BBMV were prepared by a Mg ÷
precipitation method. They were repurified on a Percoll gradient. This
step resulted in a decrease in basolateral membrane contamination
(decrease in Na-K-ATPase enrichment factor from 2 0.4 to 0.9 0.1,
N = 5 when compared to the crude homogenate). The transports of
3H-NMN [50 M] and '4C-TEA [200 .LMI were measured before and
after the repurification step at 25°C by a rapid filtration method. As
already shown in dogs and rabbits, an outwardly—directed proton
gradient (pH = 6, pH0 = 7.4) stimulated the uptake of TEA. The
transient overshoot was comparable in non-repurified (516%) and
repurified (442%) vesicles (N = 3). Therefore the repurification step did
not increase TEA transport rate. NMN uptake was stimulated by the
same proton gradient but no overshoot was observed. Fifteen second
uptakes were 14 (control) and 49(pH) pmoles/mg protein in non-
repurified vesicles. The repurification step did not either increase NMN
transport rate (IS vs. 53 pmoles/mg protein). These data suggest that in
pig BBMV, as in rabbits, TEA is transported more efficiently than
NMN.
Circulating atrial natriuretic peptide in man is increased during an
excess in either a mineralocorticoid or glucocorticoid. DR. Matter, E.E.
Matter, M.P. Gnaedinger, D.E. Uehlinger, S. Shaw, Ch. Hess, P.
Weidmann. Med. Poliklinik, University of Bern, Switzerland. To inves-
tigate the influence of an excess in either a mineralocorticoid or a
glucocorticoid in circulating atrial natriuretic peptide (ANP) and some
possible functional correlates, 8 healthy men (mean age 22 yr) received
double blind and in randomized sequence 9a-fludrocortisone acetate
(9aF), 0.6 mg/day (d), prednisone (PRED), 50 mg/d, and placebo
(PLAC) each for 9 d; the diet contained 130 mEq sodium and 75 mEq
potassium daily. Supine (I hr) ANP levels (measured by RIA after
extraction on C18 columns) were stable and 2,4 and 9 of PLAC (77
3!, 83 15, and 84 18 (SEM) pg/mi, respectively). These values
increased to 234 130 (P < 0.05), 274 106 and 288 90 pg/mI (P <
0.01), respectively, during 9csF, and to 210 113 (P < 0.05), 256 127
and 147 55 pg/mI during PRED. Compared with PLAC, sodium input
minus urinary output during 9uF averaged + 41 mEq until blood
sampling on d 2, + 112 mEq on d 4 and + 149 mEq and 9, while body
weight was unchanged on d 2 and increased by 0.7 and 1.1 kg on d 4 and
d 9, respectively; escape from 9aF-induced renal sodium retention
occurred on d 4 to d 7. During PRED, sodium input minus urinary
output averaged — 17 mEq on d 2, + 17 mEq on d 4 and —68 mEq on
d 9; body weight was not increased compared to PLAC. Twenty—four
hour creatinine clearance tended to be increased on d 4 and d 9 of 9aF
and on d 4 of PRED. Whole blood volume measured on d 9 was
increased during 9aF (5.7 0.48 vs 5.1 0.3 1 on PLAC), but not
during PRED (5.3 0.4 1). Mean arterial pressure tended to rise during
9aF (+ 3, + 6, and + 13 [P < 0.51 mmHg, respectively), but not during
PRED. Plasma renin, aldosterone and norepinephrine decreased during
9aF (P < 0.05 to <0.01), while aldosterone levels were lowered on d 9
during PRED. These findings demonstrate that mineralocorticoid or
glucocorticoid present in excess may both provoke an increase in
circulating ANP. The glucocorticoid—induced rise and the initial in-
crease in ANP during mineralocorticoid excess are due to a mechanism
other than overall sodium—fluid volume retention; a central shift of
blood volume or a direct effect of these steroids on ANP-release and/or
metabolism deserve consideration. ANP may at least in part mediate
the escape of renal sodium retention from mineralocorticoid excess and
help to prevent sodium retention during short—term high-dose PRED
treatment.
Effect of tumoral factors from human carcinoma cells on cAMP
production and sodium—dependent phosphate transport (NaP1T) in cul-
tured epithelia of two kidney cell lines. L. Pizurki, R. Rizzoli, J.
Caverzasio, J.P. Bonjour, Division de PHysiopathologie clinique,
Département de Médecine, Hôpital Cantonal Universitaire, 1211
Genève 4, Switzerland. Hypercalcemia of malignancy can be associated
with a decreased renal tubular phosphate reabsorption and hypophos-
phatemia, which have been ascribed to tumor produced factor(s)
exerting parathyroid hormone—like activity. We investigated the effect
of serum—free conditioned medium (CM) from BEN cells, derived from
a lung carcinoma of a hypercalcemic patient, and of PTH on cAMP
production and NaPiT in two renal cell lines, whicn have been recently
shown to display a NaPiT, with characteristics similar to those demon-
strated in brush border vesicles isolated from rat kidneys. In the
opossum kidney cell line (OK), PTH is known to enhance cAMP
production and inhibit NaPiT; in contrast, the LLC-PK cell line is
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devoid of PTH receptors. These lines provide tools for the evaluation of
putative PTH-like and non-PTH-like factors susceptible to influence
NaPiT. In OK cells, BEN CM induced a 3 to 4-fold increase of cAMP
production, which was blunted by the PTH inhibitor bPTH (3-34).
NaPiT, as assessed by measuring the initial rate of Pi uptake over a 4
minute period, was inhibited on a dose—dependent manner by BEN
CM, with an effect maximal between 1 hour 30 minutes and 6 hours of
incubation. At these times, NaPiT was reduced by 40 4%and 47
4%, respectively (X SEM, N = 12), corresponding to the effect
produced by 1—3 flM bPTH (1—34). Sodium—dependent transport of the
glucose analog alpha l-methylglucopyranoside (NaUT) was affected
neither by BEN CM nor by PTH. Medium collected from the human
cell line A43 1, derived from a vulva carcinoma not accompanied by
hypercalcemia did not alter NaPiT. In LLC-PK cells, neither BEN CM
nor PTH did alter cAMP production, nor NaPiT after 1 hour 30 minutes
of incubation, nor NaGT. At 6 hours, however, BEN CM caused a
slight but significant decrease of NaPiT (15 3%, N = 15). At both
times, A431 cells CM enhanced NaPiT. These results indicate that BEN
CM contains a factor which stimulates cAMP production and specifi-
cally inhibits NaPiT in cultured renal epithelium endowed with PTH
receptors. In addition to this PTH-like activity, BEN cells appeared to
secrete another factor which inhibits NaPiT without interacting with
PTH receptors.
Effects of dibutyryl cyclic guanosine monophosphate on renal function
ii Iscllemic renal failure. S.G. Shaw, P. Weidmann, J. Hodier,
Medizinische Polikiinjk, University of Berne, Switzerland. Since in-
creased levels of cyclic guanosine monophosphate (cGMP), acting as a
second messenger for atrial natriuretic peptide (ANP), may mediate the
protective action of intrarenal a-ANP infusions in ischemic renal
failure, a stable analogue, dibutyryl-cOMP (D-cGMP), was assessed for
its effects on renal function after 60 minutes of renal artery clamping
(RAC) in uniriephrectomized female Wister rats (300 20 g) under
nembutal anaesthesia. Plasma creatinine (PCr), creatinine clearance
(CCr), fractional excretion of sodium (FENa) urine flow (V), hematocrit
(HC) and mean arterial pressure (MAP) were monitored. After 60
minutes of RAC, experimental animals were infused intrarenally for 4
hours With D-cGMP (4.2 j.g/min/100 g body wt) in 0.9% saline. Sham
animals were similarly infused but the renal artery was not clamped.
Control non-clamped animals were infused only with saline. Indices of
renal function were assessed during the final 3 to 4 hr of infusion or 24
hr after RAC and D-cGMP treatment. Results 5EMa (< 0.5 vs.
controls):
Experimental
Control
Saline infused
Sham (no RAC)
D-cGMP infused
RAC & D-cGMP
infused
3—4 hr of 3—4 hr of 3—4 hr of 24 hr after
Group infusion infusion infusion infusion
5N 6 6 6
PCrmg/dl 0.46 .05 0.5 .02 1.1 .14 3.07 .8
CCR mI/mm 0.89 .15 0.81 .04 0.1 .03 0.16 .08
V mi/hr 0.45 .07 0.93 .2 1.24 •3 0.77 .2
FENa % 0.6 .18 2.54 .68a 18,98 9 12.6 3
MAPmmHg 98± 2 107± 5 98± 3 109± 9
The results show that although intrarenal D-cGMP infusion enhances
sodium and water excretion it does not simulate the protective effect of
a-ANP in ischemic renal failure. It is possible that a-ANP may
counteract post-ischemic renal failure by activation of specifically
located ANP receptors thereby producing a selective rather than
generalised modification of intrarenal cGMP.
Intrarenal atrial natriuretic peptide infusion depletes renal tissue
catecholamines during the early phase of isehemic acute renal failure.
S.G. Shaw, P. Weidmann, J. Hodier, Midizinische Poliklinik, Univer-
sity of Berne, Switzerland. Increased catecholamine levels (CA) may
contribute to the pathogenesis of post-ischemic acute renal failure
(ARF) in the rat. Aipha-atrial natriuretic peptide (a-ANP) infused for 4
hour into the renal artery immediately after 60 minutes of ischemia
produced by renal artery clamping (RAC) can prevent this type of ARF.
Therefore, we investigated the effect of a 4 hour a-hANP infusion (80 ng
(13 pi)/min in 0.9% saline + 1% albumin) on circulating and renal tissue
CA at 4 and 24 hours after 60 minutes of RAC in uninephrectomized
female Sprague Dawley rats (250 25 g) under nembutal anaesthesia.
Plasma creatinine (Cr), and arterial and renal tissue concentrations of
free norepinephrine (NE), epinephrine (E) and dopamine (DA) (by
HPLC with electrochemical detection) were measured. Control animals
received NaCl/albumin alone. Results (± SEM, ap < 0.001 versus sham
infused controls)
RAC
Sham infused controls
RAC
a-hANP infused
Normal 4 hr 24 hr 4 hr 24 hr
N= 10 N=7 N= 10 N= 10 N=5
Plasma
Cr mg/di .7 .03 1.1 .01 3.7 .2 .6 .2 .62 .03
NEng/dl 28±6 60± 19 74±30 19±4 29±5
E ng/di 42 17 290 82 100 54 46 II 15 6
DA ng/dl 25 6 125 52 28 12 9 3 22 7
Renal cortex ng/g protein
NE 1881 595 2255 334 770 243 35 4 142 37
E 18 6 172 34 133 42 18 4 32 l5
DA 128±14 160±52 40±12 29±3a 88±26
Renal medulla ng/g protein
NE 483 138 634 123 540 171 46 6 100 l5
E 14 .6 177 48 141 45 26 3 39 19
DA 65±6 117±25 34±11 47±lla 104±23
Conclusion, Dramatically reduced renal tissue CA levels, produced by
intrarenal infusion of u-hANP after 60 minutes of RAC, may form part
of the protective action of a-hANP in ARF.
The use of calcium—carbonate (CC) and calcium—gluconate (CG) as
phosphate—binder (PB) in hemodlalysis—patients (HP). W. Schulz, H.J.
Deuber, Tb. SchOlihammer, K. Famira III, Med. Klinik, Klinikum
Bamberg, Akad. Lehrkrankenhaus der Univ. Eriangen, Nürnberg,
Germany. The commonly used PB contains Al. Al is considered as the
most important factor for the development of special osteomalacias and
of the encephalopathy in HP. Therefore this study attempted to
substitute Al-containing PB by CC or CG. Methods. Twenty—five
patients, aged 51 16 (20—80) years, were treated with CC or CG up to
1 year. The Al-containing PB was reduced stepwise. Results. The
Al-containing PB could be reduced from 3712 1457 mg/day to 2000
1100 mg/day (P < 0.05). The final CC-dose was 2175 783 mg/day and
the final CG-dose was 6825 1379 mg/day. During this treatment
phosphate was reduced from 8.2 1.5 to 6.4 2.5 mg/dl. Alkaline
phosphatase was reduced from 151.8 71.2 to 118.7 52.9 U/liter.
Calcium raised from 2.3 0.2 to 2.4 0.1 mmol/liter. Conclusions. As
well CC as CU can be used as alternative PB that effectively reduces
phosphate levels and avoids Al-intoxications.
Pressure-dependence of circulating atrial natriuretic peptide during
norepinephrine infusion in man. D.E. Uehlinger, T. Zaman, P.
Weidmann, S. Shaw, M.P. Gnadinger, Medizinische Poliklinik, Uni-
versity of Berne, Switzerland. In search of a possible direct, pres-
sure—independent effect of norepinephrine on plasma levels of im-
munoreactive ANP (irANP), 10 healthy young men were studied during
intravenous infusions of norepinephrine alone or in combination with
sodium nitroprusside. The norepinephrine infusion dosage was in-
creased in four 30 minute intervals up to a final dose of 200 ng/kg body
weight/mm, leading to 12-fold higher plasma norepinephrine levels than
during control conditions. This procedure increased mean blood pres-
sure from basal values of 94 3 mm Hg (mean SEM) to 119 4 mm
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Hg (P < 0.001) and plasma irANP from 50 7 to 112 17 pg/mI (P <
0.001), whereas heart rate decreased (P < 0.001). The norepinephrine
infusion was continued at the highest dose and an additional infusion of
nitroprusside was started to titrate mean blood pressure in 30 minute
intervals down to control values. A mean dose of 0.95 pg/kg body
weight/mm nitroprusside was required to restore mean blood pressure
to 93 4 mm Hg. This was accompanied by a decrease in plasma irANP
to basal values (51 4 pg/mI; P < 0.001), an increase in heart rate (P <
0.001) and largely unchanged plasma levels of norepinephrine. Plasma
protein and hematocrit rose about 5 to 6% (P < 0.001) during the
norepinephrine infusion and decreased again 3 to 4% (P < 0.001 and P
< 0.01), when nitroprusside was added. No consistent changes were
observed for plasma levels of epinephrine, dopamine, sodium and
potassium. We conclude that a pressor infusion of norepinephrine
increases plasma irANP levels mainly through hemodynamic changes.
Interstitial fibrosis in kidney transplants. H. U. Zollinger, G. Thiel,
M.J. Mihatsch, Department of Pathology and Internal Medicine,
University of Base!, Switzerland. Interstitial fibrosis (INF) is an impor-
tant factor of the reduction of renal function in kidney transplants. One
thousand and seventy—one kidney biopsies, 574 of patients treated with
Ciclos porin (CiA) 497 of patients with conventional immunosuppres-
sion (CIS) were analyzed. (I) INF was present in 12.3% in biopsies of
CiA and in 13.0% in those of CIS treated patients. (2) Medium severe or
severe forms of interstitial cellular rejection (ICR) were found in 34% in
biopsies of CiA and 27.5% of CIS-treated patients. Severe forms of ICR
were more frequent in CIS than in CiA biopsies. (3) Analysis of repeat
biospies showed that severe ICR was not followed by INF. After
moderate ICR in the I. biopsy the second biopsy in CiA treatment
showed medium or severe INF in 11%, the corresponding figure in CIS
biopsies was 9%. Similar results were found in repeat biospies in
patients without ICR in the first biopsy. (4) In CiA and in CIS biopsies
with vascular lesions, INF was found in 19.2%, without vascular lesions
in 8.3%. In conclusion: (I) CiA treatment per se does not lead to INF;
(2) INF seems not to be the result of ICR; and (3) INF is mainly the
result of vascular lesions.
Adenosine, a mediator of the hypoxemia—induced decrease of GFR in
newborn rabbits? J.B. Gouyon, J.P. Guignard, Unite de Nephrologie,
Service de Pédiatrie, Centre Hospitalier Universitaire Vaudois, 1011
Lausanne, Switzerland. The role of the renal adenosine as a mediator of
the hypoxemia—induced decrease in glomerular filtration rate (GFR) in
immature animals was assessed in mechanically—ventilated anesthe-
tized newborn rabbits. Three groups of 8 animals were studied during a
one hour control period (I) followed, after equilibration, by a stable one
hour hypoxemic period (II). Group I: untreated animals, acting as
control group. Group 2: theophylline (0.5 mg/kg), an antagonist of
adenosine receptors, was administered iv at the start of period II.
Groupe 3: enprofylline (0.5 mg/kg), a xanthine known as a poor
adenosine competitive antagonist, was administered as in group 2. Each
animal was used as his own control. GFR and renal blood flow were
assessed by the clearances of inulin and PAH, respectively. Hypoxemia
(Pa02 = 41.1 2.0 mm Hg) was associated with a significant fall in
GFR (—15.3 7.3%, P < 0.05) in group 1. In Group 2, theophylline
completely prevented the hypoxemia (Pa02 = 41.9 1.6 mm Hg)
induced decrease in GFR, the latter remaining stable throughout the
control (2.58 0.31 mI/kg. mm) and the hypoxemic periods (2.75
0.28 mI/kg . mm). Enprofylline was totally ineffective to prevent a
significant decline in GFR (—17.7 8.0%, P < 0.05) during the
hypoxemic period (Pa02 = 39.3 1.3 mm Hg) in Group 3. The
extraction of PAH was not significantly different in normoxemic (54.6
3.7%), untreated—hypoxemic (45.7 4.6%) and theophylline (50.0
6.8%) or enprofylline (51.4 7.2%) treated hypoxemic animals. The
following changes in RBF and RVR were recorded from the control to
the hypoxemic periods: Group 1, —8.6 8.9% (NS) and + 20.5
ll.6%(NS);Group2, —2.8 5.7%(NS)and +2.3 9.0%(NS);Group
3, 21.0 8.0% (P < 0.05) and + 29.5 12.6% (P < 0.05). The overall
results in groups 1, 2 and 3 suggest that adenosine could mediate, at
least in part, the hypoxemia—induced decrease in GFR in immature
animals by increasing renal vascular resistance.
Metabolic alkalosis induced by co-administration of a "non-systemic"
antiacid and calcium polystyrene in a hemodialyzed patient. J.P.
Guignard, D. Tzogalis, E. Gautier, Unite de Néphrologie, Service de
Pédiatrie, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne,
Switzerland. The administration of "nonabsorbable" alkali or that of
cation—exchange resins does not usually induce an acid—base distur-
bance. Severe metabolic alkalosis occurred however in a boy undergo-
ing long—term maintenance hemodialysis, in the absence of vomiting or
gastric drainage. At the age of 8 years, L.W. presented with severe
metabolic acidosis and terminal renal failure secondary to
nephronophtisis. He was started on a 3 times—a—week hemodialysis
program and given aluminum hydroxide (I g/day) and calcium polysty-
rene (10—15 g/day) in order to prevent hyperphosphatemia and
hyperkalemia, respectively. In the following weeks he repeatedly
presented with focal motor seizures. Pre-dialysis blood acid—base
analysis revealed severe metabolic alkalosis, with plasma bicarbonate
and pH reaching levels as high as 49.3 and 7.60 mmol/liter, respectively.
Addition of alkali to body fluids in this anephric patient when the
antiacid and the calcium resin were administered concomitantly is
explained by the formation of an aluminum resin complex in the
stomach, and the subsequent absorption of bicarbonate from pancreatic
and intestinal secretions. The separate administration of the antiacid
and the resin resulted in the normalization of plasma bicarbonate
concentration. The latter rose again however when Al(OH)3 adminis-
tration was increased to 5 g/day. Complete correction of the alkalosis
was only achieved when a complex salt of Al (Al9 (OH)8 Cl19 23H20),
rather than Al(OH)3 was used as a phosphate binder. The possible
occurrence of severe metabolic alkalosis in anephric patients given a
nonabsorbable antiacid and a cation—exchange resin requires that the
administration of the two agents be separated by several hours, or that
the antiacid be administered in a complex form, such as aluminum
hydroxydatum chloratum hydratum.
Measurement of inulin and PAH clearances in clinical conditions:
artefacts and interferences. F. Zihlmann, 0. Grigoras, J.P. Guignard,
Unite de Néphrologie, Service de Pédiatrie, Centre Hospitalier
Universitaire Vaudois, /011 Lausanne, Switzerland. Accurate mea-
surement of GFR and renal plasma flow (RPF) is essential in
physiopathological clinical studies as well as in the precise follow—up of
patients with renal disease. Inulin and paraaminohippuric acid are the
standard markers of GFR and RPF, respectively. Inulin is analyzed
after hydrolysis to fructose, and PAH after diazotization by sodium
nitrate, both being measured spectrophotometrically after reacting with
an appropriate reagent. Clinical studies are usually performed in well
hydrated patients, optimal hydration being maintained by generous
drinking. Inulin determination. Various beverages, drug preparations
and foods can artefactually raise 'inulin readings" in plasma and urine
by releasing "hidden" D-fructose. Ingestion of 1 g fructose/kg body wt,
as contained in natural drinks, can raise the "inulin" plasma concen-
tration to a level of 14 2 mg%. Similarly, ingestion of I g sac-
charose/kg body wt in a cup of tea or in drug—containing syrups, raises
the "inulin" plasma concentration by 6.4 2 mg%. After ingestion,
appearance of fructose in plasma and subsequent excretion in the urine
is rapid, peak urinary levels being attained within 60 to 90 minutes.
Artificial sweeteners, such as saccharin and cyclamate do not interfere
with inulin determination. PAH determination. Various substances
containing an aminobenzoic ring such as the sulfanilamides or procaine
have been known to interfere in the measurement of PAH. Among a
new group of widely used drugs, the beta—blockers, some agents also
artefactually raise the PAH concentration. Administration of acebuto-
lol, 6 mg/kg, to a 30 kg child, gives a "PAH reading" of 1.15 mg%, in
the absence of PAH infusion. We conclude that the precise measure-
ment of inulin and PAH clearances requires that interfering substances
be always carefully searched for, and their administration avoided both
before and during the clearance study.
Anderson—Fabry's disease without cutaneous involvement: Study of a
36 membership family. F. Saurer, L. Humair, A. de Torrente, Hôpital
Communal, 2300 La Chaux—de—Fonds, Switzerland. A 40 year—old
male suffering from nephrotic syndrome had a renal biopsy showing the
typical features of Fabry's disease. Thirty—six members of his family
were located. Twenty-eight underwent the following investigations: (1)
complete clinical examination. (2) Plasma creatinine and creatinine
clearance. (3) Ophtalmic examination in 12 females and 3 males. (4)
Plasma y galactosidase. (5) Urinary excretion of triexoside ceramide.
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These investigations confirmed the diagnosis (clinical and biological) in
2 males and detected 3 female carriers. Only 3 patients had paresthe-
sias, none had cutaneous lesions, all had eye involvment. In the patients
who were not available for examination, family history revealed that 3
males and I female died of renal failure and that all suffered from
paresthesias. In our study, the ophtalmic examination proved to be the
simplest way to confirm the clinical picture or the carrier state. It is
remarkable that no patient had any cutaneous lesions.
Growth in children with chronic renal failure (CRF) before and after
renal transplantation (TPL): Results of a prospective study in Switzer-
land. E.P. Leumann, F. Egli, A. Fanconi, J.P. Guignard, R. Koegel, 0.
Oetliker, L. Paunjer, Unjversitäts—Kinderklinik, Zurich, Switzerland.
Data on growth in CRF are often biased by selection of patients. We
therefore evaluated growth from data obtained since 1973 in all pediat-
ric patients with CRF (serum creatinine >180 smol/liter) living in
Switzerland. Growth was assessed separately for patients (I) on con-
servative treatment, (2) at ESRD, i.e. begin of dialysis or death from
uraemia, and (3) after cadaveric renal TPL (minimum observation
period 3 years, conventional immunosuppression). Patients with cysti-
nosis/oxalosis were excluded. Results: (I.) Growth on conservative
treatment was satisfactory in 12 of 26 boys (46%) and 7 of 22 girls (32%).
Satisfactory growth was explained in only 5 of these 19 patients: 4 had
GFR >25 mI/mm per 1.73 m2, and one had received vitamin D
metabolites for severe osteodystrophy. (2.) Average height deficit at
ESRD was 1.79 SDS in 36 boys and 1.52 SDS in 41 girls subsequently
treated by dialysis. In contrast, average height in 12 untreated male
patients was —2.96 SDS. Severest height deficit occurred in patients
with focal segmental sclerosis (N = 6), urologic anomalies (8) and
hypo-dysplasia (5). (3.) Growth after TPL was poor not only in 7 of 8
patients with reduced graft function, but also in 6 of 14 (43%) with good
function. Conclusions. Growth on conservative treatment has been
satisfactory in only 40% of patients. Good graft function is a prerequi-
site, but no guarantee for satisfactory growth in patients on conven-
tional immunosuppression.
Intraperitoneal administration of ceftriazone in CAPD-patients. M.
Rastorfer, K. Zdruba, P.J. Probst, Nierenstation Stadtspital Waid
Zurich und Abteilung für Klinische Forschung F. Hoffmann—La Roche
& Co. AG, Base!, Switzerland. In 6 patients on CAPD without
peritonitis it has been tested if by means of intraperitoneally adminis-
tered Ceftriaxone (CR0) sufficient plasma concentrations could be
achieved as well as high local concentrations in the peritoneal cavity.
During the study of 48-hours there were 4 exchanges of 2 liters dialysate
per day (dwell time: 5-5-6-8 hr). CR0 was applicated into each dialysate
bag only during the first 24 hours (1St bag: 500 mg, 2nd—4th bag: 250
mg), followed by 24 hr of dialysis without any further antibiotic
treatment. With this dosage regimen in 4 patients plasma levels of 20 to
50 mg/liter had been achieved at 24 hr. which decreased to values
between 4 and 15 mg/liter within the following 24 hr. In these 4 patients
CR0 was eliminated from plasma with a tl/2 of 10—13 hr. The 2
remaining patients showed somewhat different results: in one patient
the elimination of ceftriaxone was extremely slow (half—life about 37
hr), resulting in a certain accumulation so that his plasma concentration
was 80 mg/liter at 24 hr and still 64 mg/liter after 48 hr. In contrast to
this, another patient showed a very short ceftriaxone half—life (approx.
4.5 hr), with plasma concentrations of 17.5 and <1.0 mg/liter at 24 and
48 hr, respectively. In the dialysis fluid concentrations of ceftriaxone at
the end of the 4th dwell period (at 24 hr) ranged between 6.4 and 44
mg/liter at 24 hr and between <1 and 9.6 mg/liter at 48 hr. Conclusion.
By means of intraperitoneally administered CR0 given into each
dialysate bag during 24 hours, concentrations are maintained in the
pentoneal cavity which are well above the MIC values of most
gram—negative pathogen organisms being potential causes of endoge-
nous peritonitis in CAPD—patients, Simultaneous plasma levels are also
high, so that it is possible to treat by intraperitoneal administration also
infections in other compartments in the peritoneal cavity.
Early adaption of cyclosporin A dose to blood levels and its influence on
function and survival of kidney—transplants. H. Heule, F. W. Reutter, P.
Bruh/mann, W. Brunner, D. Sege, Medizinische Klinik B und
Chirurgische K!inik, Kantonsspital, CH-9007 St. Gallen, Germany.
From May 1983 to December 1985, 39 consecutive cadaver renal—
tranpiantations were performed with cyclosporin A (CyA) and low dose
prednisone as immunosuppresants. Two protocols were used and
results compared:
Protocol A
(N = 19)
Protocol B(N = 20)
CyA first 2—3 days
CyA after 2nd or 3rd
5 mg/kg i.v.
15mg/kg p.o.
4 mg/kg i.v. 1 a
12 mg/kg p.o.)
day
Adaption of dosage q 2 weeks twice per week
Attempted CyA blood 400—800 ng/ml 400—600 ng/ml 1st month
level 300—600 ng/ml 2nd month
150—400 ng/ml past 7 months
a Halfdose in case of tubular necrosis with addition of ATG 1 mg/kg
until excretory function present
Results:
Protocol A
Patient survival
.
Transplantat survival
1 lyearj
94%
94%
S-creatinine 3 months 185 52 tmol/liter
5-creatinine 12 months 227 103 smol/liter
CyA-level 1 month 1009 361 ng/ml
CyA-dosis 1 month 84 mg/kg
Protocol B Significance
100% NS
94% NS
115 20 prnol/liter P < 0.001
125 128 smol/liter P < 0.05
468 128 ng/ml P < 0.001
6,6 mg/kg P < 0.05
Conclusion. Early, continuous dose adaption of CyA allows avoidance of
CyA blood levels in the toxic range with significantly improved transplant
function and survival at 3 and 12 months after transplantation.
Mesangial.proliferative glomerulonephritis in a patient with
sarcoidosis. C. Hug, F. W. Reutter, F. Gloor, Medizinische Klinik B und
Institut für Pathologie, Kantonsspital, CH-9007 St. Gal/en, Germany.
Renal involvement in sarcoidosis is well known. Interstitional nephritis
with or without granulomatas, nephrocalcinosis and nephrolithiasis are
the prime manifestations of renal sarcoidosis. The association of
glomerulonephritis and sarcoidosis is less known. I the case of a
25-year—old male with renal insufficiency (creatinine 396 smol/liter),
hypercalcemia (2.9 mmol/liter), elevated I ,25-dihydroxyvitamin D and
renal glucosuria was presented. Renal biopsy demonstrated, in addition
to interstitional nephritis with tuberculoid granulomatas, mesangial
hypercellularity. On electronmicroscopy numerous dense deposits
were present in the mesangium and at the mesangio-capillary junction.
Immunfluorescence demonstrated focal—segmental deposits of 1gM,
IgA, Clq, C3, C9, mostly in the periphery. The diagnosis of dissemi-
nated sarcoidosis are proved by numerous productive tuberculoid
granulomatas in bronchial and lung biopsies. The association of
sarcoidosis and glomerulonephritis seems more than coincidental. A
common immunpathogenesis is possible but not proven.
